Evidence map›Paper›PMID 41395491›Full record

ArticleFrontiers in microbiology2025

Decoding drug tolerance: insights into the

Min Li, Yun Wang, Xiaohong Xiang, Lingling Dong, Qiming Li, Zhou Liu, Wenwen Chu, Ye Naifang, Zhen Gong, Qiang Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Min Li *Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yun Wang *Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Xiaohong Xiang *School of Pharmacy, Chongqing Medical and Pharmaceutical College, Chongqing, China.
Lingling DongDepartment of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Qiming LiDepartment of Clinical Laboratory, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, China.
Zhou LiuDepartment of Clinical Laboratory Center, Anhui Chest Hospital, Hefei, China.
Wenwen ChuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Ye NaifangDepartment of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Zhen GongDepartment of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Qiang ZhouDepartment of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Isoniazid is widely used in the treatment of pulmonary tuberculosis, yet the mechanisms underlying its tolerance remain incompletely understood. The Methods: We generated an MSMEG_0608 knockout strain and performed drug susceptibility testing, growth curve analysis, biofilm formation assays, transcriptomic profiling, and RT-qPCR validation. Complementation with Results: The deletion of Discussion: Our results suggest that

Indexed as

drug toleranceglyoxalaseisoniazidMycobacterium tuberculosisRv0274

Identifiers

PMID41395491
PMCPMC12695796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.